Nature Reviews Gastroenterology & Hepatology

Article	Citations
Regulating protease homeostasis in irritable bowel syndrome	641
Hybrid EASL Congress 2023	484
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity	447
Zolbetuximab treatment in metastatic gastric cancer	425
2023 FDA approvals in gastroenterology and hepatology	404
Western lifestyle, metaflammation and the cell of origin of colon cancer	349
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	340
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	326
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	313
Digestive Disease Week 2022	305
Mapping neuroimmune interactions in the gut	301
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	282
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	275
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection	266
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	257
Nomenclature of HBV core protein-targeting antivirals	252
Artificial intelligence and automation in endoscopy and surgery	239
Leveraging diet to engineer the gut microbiome	216
Oral microbiome therapy efficacious for recurrent C. difficile infection	201
Hepatic IRF3 in glucose intolerance	201
Wound healing in the colon	191
A crucial Fusobacterium nucleatum clade in colorectal cancer	185
GWAS reveals variants for alcohol-related hepatocellular carcinoma	176
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	169
Metastatic pancreatic cancer and the liver	168

Decoding therapy resistance in liver tumours: a giant leap	161
A deep dive into the submerged ‘coeliac iceberg’	159
New understanding of hepatobiliary MRI	157
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	156
Inflammatory bowel disease in pregnancy and breastfeeding	152
The global burden of coeliac disease: opportunities and challenges	151
Bacteriophages and their potential for treatment of gastrointestinal diseases	151
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	145
Advancing on pancreatic cancer	144
Dietary carbohydrates and fats in nonalcoholic fatty liver disease	143
HDCA ameliorates NAFLD in mice	140
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	139
Integrated systems approach to identify environmental factors in intestinal inflammation	139
Metabolic diseases in the East Asian populations	133
Therapeutic base editing in the adult liver	128
Lanifibranor and NASH resolution	127
Probiotics for preterms: sharing complex decision-making	121
Implications of the evolving knowledge of the genetic architecture of MASLD	118
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	111
Medical therapy of paediatric inflammatory bowel disease	110
Preventing the progression of cirrhosis to decompensation and death	108
Estimating dietary intake from human stool DNA	108
Characterizing the genomic landscape of colorectal cancer	106
Human intestinal B cells in inflammatory diseases	101
SSRIs and depression: role of gut–brain communication	101
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	100
Transglutaminase 2 inhibitor for coeliac disease	100
The path to successful hepatitis C elimination in Spain	100
Current and future colorectal cancer screening strategies	97
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	97
ECCO’24	96
Transforming the landscape of liver cancer detection and care	95
Author Correction: Hepatic immune regulation and sex disparities	92
A single-cell atlas of fibroblasts: one size does not fit all	91
Yeast probiotics for the treatment of IBD	91
NAFLD prevalence in older patients with T2DM	89
Phase III results for first-line treatment for metastatic colorectal cancer	88
Gut microbiome and autism spectrum disorder	85
Microbiota and colorectal cancer — controlling for confounders challenges associations	85
Enteric nervous system transfers stress to the gut	83
GLP1R agonists in NAFLD: a promising therapy on the horizon	82
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	82
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	80
Publisher Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	79
Artificial intelligence in liver cancer — new tools for research and patient management	76
Foundations of gastrointestinal-based drug delivery and future developments	76
Neutrophils as potential therapeutic targets in hepatocellular carcinoma	76
Hepatic glucose metabolism in the steatotic liver	76
Immunoregulatory role of enteric glia	73
Hepatic inflammatory responses in liver fibrosis	73

SMART cancer risk prediction	72
Liver dialysis in ACLF	71
AI predicts pancreatic cancer risk	69
The gut microbiome in feast and famine	65
Elucidating the transmission landscape of the human microbiome	65
Gut bacteria go on record	64
Nifty new tools for microbiome treatment design	64
A new era in obesity management	62
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel	62
International collaborative research to improve gallbladder cancer prevention	60
Postbiotics — when simplification fails to clarify	59
MASLD as a non-communicable disease	57
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	57
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	53
Hepatitis E virus: from innate sensing to adaptive immune responses	50
Revisiting fibrosis in inflammatory bowel disease: the gut thickens	48
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	47
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests	47
Danger! P2Y14 receptor links cell death to liver fibrosis	45
Tirzepatide to treat obesity: phase III results	44
Publisher Correction: Publisher Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	43
Nivolumab plus chemotherapy for advanced gastric cancer and oesophageal adenocarcinoma	41
A novel pathomics signature for gastric cancer	39
Cathepsin S in liver fibrogenesis	39
Origin of CAFs in colorectal cancer	39
Cellular and molecular basis of proximal small intestine disorders	38
Antibiotic-perturbed microbiota and the role of probiotics	38
The steatotic liver disease burden paradox: unravelling the key role of alcohol	36
Bridging the gap: increasing MENA representation in MASLD clinical trials	35
Natural history of NAFLD: knowns and unknowns	34
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	34
Commensal fungi in intestinal health and disease	34
Classifying compounds as prebiotics — scientific perspectives and recommendations	31
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	30
Therapeutic landscape and future direction of metastatic colorectal cancer	30
Long-term normothermic liver perfusion	30
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	30
Author Correction: Improving IBD outcomes in the era of many treatment options	30
Justice, equity, diversity and inclusion in gastroenterology and hepatology	29
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	28
Author Correction: Current and future colorectal cancer screening strategies	28
Diet-driven microbiome restoration associated with cardiometabolic benefits	26
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	25
Alcohol-free and low-strength drinks: friend or foe?	25
Hippo signalling in the liver: role in development, regeneration and disease	24
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	24
Global epidemiology of cirrhosis — aetiology, trends and predictions	24
A Roadmap for the Human Gut Cell Atlas	24
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	24
Resmetirom safe for nonalcoholic fatty liver disease	23
Location, location, location — spatial insight into hepatic macrophage populations	22
Intermittent fasting for NASH and HCC in mice	22
Digestive Disease Week 2023	22
New target and timing in PDAC immunotherapy?	22
ECCO’25	21
Elafibranor in primary biliary cholangitis	21
Deciphering potential implications of dietary microplastics for human health	21
Digestive Disease Week 2025	21
A resource for the food microbiome and its links with the human microbiome	21
Follow-up of SER-109 for recurrent C. difficile	20
Envisioning how to advance the MASH field	20
Human liver tissue in a mouse host	20
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	20
Gastrointestinal health and the environment: a bidirectional relationship	20
Food inequity and insecurity and MASLD: burden, challenges, and interventions	20
Nanoparticles in NAFLD therapeutics	19
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	19
HCV direct-acting antiviral therapy adherence in people who inject drugs	19
Envisioning adalimumab for paediatric patients with ulcerative colitis	18
Amitriptyline as second-line treatment for IBS in primary care settings	18
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	17
IL-17A-producing CD8+ T cells in pancreatic cancer	17
Lactylation and HCC progression	17
COVID-19 and liver disease: where are we now?	17
Gastrointestinal post-acute COVID-19 syndrome	17
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	17
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	16
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	16
Early detection of pancreatic cancer using DNA-based molecular approaches	16
The need to integrate basic science and medicine in patient education resources	15

Moving towards more patient-centred clinical trials in IBD	15
Liver steatosis and fibrosis in China	14
Biologic agents for IBD come of age as host–microbe interactions emerge	14
Mapping the malignant transformation from polyps to CRC	14
Paving the way: the road to be taken for proper NAFLD health care	14
Elucidating the link between clonal haematopoiesis and chronic liver disease	13
Combination treatment further extends survival	13
Mucus secretion from colonic goblet cells is regulated by autophagy and ER stress	13
Elucidating the nutrient preferences of mouse gut bacteria	13
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards	12
‘Dark matter’ beyond the bacteria in faecal microbiota transplantation	12
Secretory IgA: controlling the gut microbiota	12
Maintaining remission in ulcerative colitis	12
AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD	12
Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions	12
Host–pathobiont interactions in Crohn’s disease	11
Author Correction: Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	11
Positioning therapies for the management of inflammatory bowel disease	11
Neoadjuvant chemotherapy for operable colon cancer	10
Actions of thyroid hormones and thyromimetics on the liver	10
Paracellular permeability and tight junction regulation in gut health and disease	10
Fermented foods and gastrointestinal health: underlying mechanisms	10
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation	9
Liver transplantation plus chemotherapy improved survival in patients with colorectal liver metastasis	9
Sex bias in clinical trials in gastroenterology and hepatology	9
Liquid biopsy guides anti-EGFR rechallenge in metastatic CRC	9
Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy	9
A bloody disgrace — time to change patient safety culture	9
Cellular triads in T cell liver tumours	9
Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease	8
Precision models in hepatocellular carcinoma	8
The war on pancreatic cancer: progress and promise	8
Redefining cancer care: the case for an onco-gastroenterology subspecialty	8
Mechanisms of metastatic colorectal cancer	8
Diversity, development and immunoregulation of enteric neurons	8
IgG4-related diseases of the digestive tract	8
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity	7
CXCR2 inhibition in NASH-HCC	7
Stigma: a major barrier to hepatitis B elimination	7
Anatomy-preserving adjustable intragastric balloon is safe and promotes durable weight loss	7
Liraglutide treatment in children with obesity	7
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications	7
Microbiome-targeted diets that alter immune status	7
An expert panel Consensus Statement on ALD without experts by experience	7
Connecting with the community	7
Understanding the therapeutic toolkit for inflammatory bowel disease	6
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders	6
Rhythmicity of infant microbiota and dietary effects	6
Molecular landscape of NASH-HCC	6
Rome Foundation Working Team Report on overlap in disorders of gut–brain interaction	6
Human hepatocyte organoids model early NAFLD	6
Crosstalk between enteric neurons and colorectal cancer stem cells influences self-renewal	6
Contrasting aspects of human excreta	6
The appendix and ulcerative colitis — an unsolved connection	6
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?	6
NAFLD, MAFLD and obesity: brothers in arms?	6
Effect of bariatric surgery on risk of oesophagogastric cancer	6
No beneficial effect of G-CSF in treating ACLF	6
Novel interventions against alcohol-related liver disease	5
Machine perfusion of the liver: applications in transplantation and beyond	5
Author Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	5
Combination therapy with methotrexate in paediatric Crohn’s disease	5
Filgotinib for ulcerative colitis	5
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	5
Fetal liver development and implications for liver disease pathogenesis	5
Pouchitis: pathophysiology and management	5
Hepatitis C testing, treatment and prevention in low- and middle-income country prisons	5
Metabolic health across the ages: how microbiota members support our well-being	5
Exploring liver cancer biology through functional genetic screens	5
Colonoscopy screening and risk of CRC	5
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape	4
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	4
Friend or foe? The elusive role of hepatic stellate cells in liver cancer	4
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease	4
The promise of the gut microbiome as part of individualized treatment strategies	4
Safety of in utero exposure to maternal IBD pharmacotherapies	4
Standardized reporting of gastroenterology-related social media scholarship for career advancement	4
Mechanisms and pathophysiology of Barrett oesophagus	4
Gut feelings: mechanosensing in the gastrointestinal tract	4
CIDEB variants protect against liver disease	4
Liver fibrosis with methotrexate — an overestimated risk?	4
The immune microenvironment in gastric adenocarcinoma	4
Lenvatinib plus EGFR inhibition for liver cancer	4
Benign liver tumours: understanding molecular physiology to adapt clinical management	4
Women in endoscopy: leading the way	4
Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome	3
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology	3
Congenital diarrhoea and enteropathy genetics	3
Break the taboo with poo	3
Reduction in colorectal cancer incidence by screening endoscopy	3
Understanding the physiology of human defaecation and disorders of continence and evacuation	3
Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies	3
MASH-induced senescence and liver cancer	3
Unravelling the genetics of irritable bowel syndrome	3
Embracing many rainbows: the realities of being a gay physician, mother and patient	3